These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 30196907)

  • 1. Biomarkers of response to immune checkpoint blockade in cancer treatment.
    Fujii T; Naing A; Rolfo C; Hajjar J
    Crit Rev Oncol Hematol; 2018 Oct; 130():108-120. PubMed ID: 30196907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring immune-checkpoint blockade: response evaluation and biomarker development.
    Nishino M; Ramaiya NH; Hatabu H; Hodi FS
    Nat Rev Clin Oncol; 2017 Nov; 14(11):655-668. PubMed ID: 28653677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers for immune checkpoint inhibitors: The importance of tumor topography and the challenges to cytopathology.
    Clark DP
    Cancer Cytopathol; 2018 Jan; 126(1):11-19. PubMed ID: 29131530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.
    Chen PL; Roh W; Reuben A; Cooper ZA; Spencer CN; Prieto PA; Miller JP; Bassett RL; Gopalakrishnan V; Wani K; De Macedo MP; Austin-Breneman JL; Jiang H; Chang Q; Reddy SM; Chen WS; Tetzlaff MT; Broaddus RJ; Davies MA; Gershenwald JE; Haydu L; Lazar AJ; Patel SP; Hwu P; Hwu WJ; Diab A; Glitza IC; Woodman SE; Vence LM; Wistuba II; Amaria RN; Kwong LN; Prieto V; Davis RE; Ma W; Overwijk WW; Sharpe AH; Hu J; Futreal PA; Blando J; Sharma P; Allison JP; Chin L; Wargo JA
    Cancer Discov; 2016 Aug; 6(8):827-37. PubMed ID: 27301722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive Biomarkers for Checkpoint Immunotherapy: Current Status and Challenges for Clinical Application.
    Tray N; Weber JS; Adams S
    Cancer Immunol Res; 2018 Oct; 6(10):1122-1128. PubMed ID: 30279188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients' selection.
    Banna GL; Passiglia F; Colonese F; Canova S; Menis J; Addeo A; Russo A; Cortinovis DL
    Crit Rev Oncol Hematol; 2018 Sep; 129():27-39. PubMed ID: 30097235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review.
    Teng F; Meng X; Kong L; Yu J
    Cancer Lett; 2018 Feb; 414():166-173. PubMed ID: 29155348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer.
    van Dam LS; de Zwart VM; Meyer-Wentrup FA
    Pediatr Blood Cancer; 2015 Feb; 62(2):190-197. PubMed ID: 25327979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer.
    Hu ZI; Ho AY; McArthur HL
    Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):153-164. PubMed ID: 28816141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PDL-1/PD1 inhibitors: antibody or antinobody?
    Aoun F; Rassy EE; Assi T; Kattan J
    Future Oncol; 2017 Aug; 13(19):1669-1671. PubMed ID: 28831825
    [No Abstract]   [Full Text] [Related]  

  • 11. Biomarkers of response to PD-1/PD-L1 inhibition.
    Maleki Vareki S; Garrigós C; Duran I
    Crit Rev Oncol Hematol; 2017 Aug; 116():116-124. PubMed ID: 28693793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection.
    Iivanainen S; Koivunen JP
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31952311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].
    Duruisseaux M; Lize-Dufranc C; Badoual C; Bibeau F
    Ann Pathol; 2017 Feb; 37(1):46-54. PubMed ID: 28131419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune cell profiling in the age of immune checkpoint inhibitors: implications for biomarker discovery and understanding of resistance mechanisms.
    Lim SY; Rizos H
    Mamm Genome; 2018 Dec; 29(11-12):866-878. PubMed ID: 29968076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Checkpoint Blockade in Breast Cancer Therapy.
    Bu X; Yao Y; Li X
    Adv Exp Med Biol; 2017; 1026():383-402. PubMed ID: 29282694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress of immune checkpoint therapy in the clinic (Review).
    Fan Y; Zhang C; Jin S; Gao Z; Cao J; Wang A; Li D; Wang Q; Sun X; Bai D
    Oncol Rep; 2019 Jan; 41(1):3-14. PubMed ID: 30365127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Towards In Silico Prediction of the Immune-Checkpoint Blockade Response.
    Chen K; Ye H; Lu XJ; Sun B; Liu Q
    Trends Pharmacol Sci; 2017 Dec; 38(12):1041-1051. PubMed ID: 29089139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. De-novo and acquired resistance to immune checkpoint targeting.
    Syn NL; Teng MWL; Mok TSK; Soo RA
    Lancet Oncol; 2017 Dec; 18(12):e731-e741. PubMed ID: 29208439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis.
    Reddy HG; Schneider BJ; Tai AW
    Clin Transl Gastroenterol; 2018 Sep; 9(9):180. PubMed ID: 30228268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hallmarks of response to immune checkpoint blockade.
    Cogdill AP; Andrews MC; Wargo JA
    Br J Cancer; 2017 Jun; 117(1):1-7. PubMed ID: 28524159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.